Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

34.49USD
8 Dec 2016
Change (% chg)

$0.58 (+1.71%)
Prev Close
$33.91
Open
$33.91
Day's High
$34.57
Day's Low
$33.16
Volume
377,495
Avg. Vol
812,268
52-wk High
$63.73
52-wk Low
$8.00

SRPT.OQ

Chart for SRPT.OQ

About

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in... (more)

Overall

Beta: 1.89
Market Cap(Mil.): $1,851.16
Shares Outstanding(Mil.): 54.59
Dividend: --
Yield (%): --

Financials

  SRPT.OQ Industry Sector
P/E (TTM): -- 41.20 30.65
EPS (TTM): -5.27 -- --
ROI: -85.52 -0.59 15.23
ROE: -91.56 -1.31 16.56

Trump presidency could prove a salve for pharma merger deals

NEW YORK Biotechnology companies, whose U.S. shares soared Wednesday after Republican Donald Trump's presidential election, may soon see another benefit: an uptick in biotech M&A. | Video

Nov 11 2016

RPT-Trump presidency could prove a salve for pharma merger deals

NEW YORK, Nov 11 Biotechnology companies, whose U.S. shares soared Wednesday after Republican Donald Trump's presidential election, may soon see another benefit: an uptick in biotech M&A.

Nov 11 2016

Trump presidency could prove a salve for pharma merger deals

NEW YORK, Nov 11 Biotechnology companies, whose U.S. shares soared Wednesday after Republican Donald Trump's presidential election, may soon see another benefit: an uptick in biotech M&A.

Nov 11 2016

BRIEF-Sarepta Therapeutics Q3 loss per share $1.18

* Sarepta Therapeutics announces third quarter 2016 financial results and recent corporate developments

Oct 27 2016

Anthem won't cover first FDA-approved Duchenne drug

Oct 7 Health insurer Anthem Inc said it would not cover the first U.S. Food and Drug Administration-approved Duchenne muscular dystrophy (DMD) drug, developed by Sarepta Therapeutics Inc, calling it "investigational and not medically necessary".

Oct 07 2016

Sarepta partners with UK's Summit on Duchenne drugs

Sarepta Therapeutics Inc said it secured the European rights to Summit Therapeutics Plc's experimental Duchenne muscular dystrophy (DMD) drug as it looks to build on its lead in treating the fatal muscle-wasting disease.

Oct 04 2016

UPDATE 3-Sarepta partners with UK's Summit on Duchenne drugs

Oct 4 Sarepta Therapeutics Inc said it secured the European rights to Summit Therapeutics Plc's experimental Duchenne muscular dystrophy (DMD) drug as it looks to build on its lead in treating the fatal muscle-wasting disease.

Oct 04 2016

BRIEF-Summit's agreement with Sarepta also contains a standstill provision

* Collaboration agreement with Sarepta also contains a standstill provision - SEC filing

Oct 04 2016

BRIEF-Sarepta Therapeutics reports pricing of $300 million public offering of common stock

* Sarepta Therapeutics announces pricing of $300 million public offering of common stock

Sep 22 2016

BRIEF-Sarepta Therapeutics announces offering to sell up to $225 mln of stock

* Sarepta Therapeutics announces proposed public offering of common stock

Sep 21 2016

Earnings vs. Estimates